San Francisco VA Health Care System, San Francisco, CA.
University of California, San Francisco, San Francisco, CA.
Diabetes Care. 2019 Nov;42(11):2075-2082. doi: 10.2337/dc19-0723. Epub 2019 Aug 30.
Experimental studies have implicated soluble (s)CD14, an effector of lipopolysaccharide-induced inflammation, in insulin resistance, but its role in human metabolic endotoxemia has not been studied. We evaluated sCD14 in relation to dysglycemia in older adults and how this compares to other markers of inflammation.
We investigated associations of sCD14, interleukin-6 (IL-6), CRP, and white blood cell (WBC) count with insulin resistance (quantitative insulin-sensitivity check index and HOMA 2 of insulin resistance) and incident type 2 diabetes in a population-based cohort of older adults. We also assessed the causal role of sCD14 in insulin resistance using an instrumental variable approach by Mendelian randomization.
After adjustment for conventional risk factors, each of the four biomarkers showed positive cross-sectional associations with both insulin resistance measures. These associations persisted after mutual adjustment for all markers except sCD14. Over a median follow-up of 11.6 years, 466 cases of diabetes occurred. All biomarkers except sCD14 were positively associated with diabetes, although only WBC count remained associated (hazard ratio 1.43 per doubling [95% CI 1.07, 1.90]) after mutual adjustment. Instrumental variable analysis did not support a causal role for sCD14 in insulin resistance.
Among older adults, sCD14 was associated with insulin resistance, but this disappeared after adjustment for other biomarkers, showed no evidence of a causal basis, and was not accompanied by a similar association with diabetes. IL-6, CRP, and WBC count were each associated with insulin resistance and diabetes, WBC count most robustly. These findings do not support a central role for sCD14, but they highlight the preeminence of WBC count as an inflammatory measure of diabetes risk in this population.
实验研究表明,可溶性 CD14(sCD14)是脂多糖诱导炎症的效应物,与胰岛素抵抗有关,但它在人类代谢性内毒素血症中的作用尚未得到研究。我们评估了 sCD14 与老年人糖代谢异常的关系,以及其与其他炎症标志物的关系。
我们在一个基于人群的老年成年人队列中研究了 sCD14、白细胞介素 6(IL-6)、C 反应蛋白(CRP)和白细胞计数与胰岛素抵抗(定量胰岛素敏感性检查指数和 HOMA 2 胰岛素抵抗)和 2 型糖尿病发病的相关性。我们还通过孟德尔随机化的工具变量方法评估了 sCD14 在胰岛素抵抗中的因果作用。
在调整了常规危险因素后,四种生物标志物中的每一种都与两种胰岛素抵抗指标呈正相关。这些相关性在除 sCD14 以外的所有标志物相互调整后仍然存在。在中位数为 11.6 年的随访期间,发生了 466 例糖尿病病例。除 sCD14 外,所有标志物均与糖尿病呈正相关,尽管只有白细胞计数在相互调整后仍与糖尿病相关(风险比 1.43,每增加一倍 [95%CI 1.07,1.90])。工具变量分析不支持 sCD14 在胰岛素抵抗中的因果作用。
在老年人中,sCD14 与胰岛素抵抗相关,但在调整其他生物标志物后,这种相关性消失,没有证据表明其具有因果关系,并且与糖尿病没有类似的相关性。IL-6、CRP 和白细胞计数均与胰岛素抵抗和糖尿病相关,白细胞计数最为显著。这些发现不支持 sCD14 起核心作用,但它们突出了白细胞计数作为该人群糖尿病风险的炎症标志物的首要地位。